Endocrinology

A recent study has suggested the efficacy of a common type 2 diabetes treatment in improving cardiac structure and metabolic control.

Li and Shao discussed the T2D risk reduction seen over the course of the VA MOVE! lifestyle intervention program for veterans.

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Findings showed GLP-1 RAs reduced the risk of overall dementia, particularly Alzheimer’s disease and non-vascular dementias, compared with metformin.

Presented at ENDO 2025, crinecerfont exhibited sustained androgen reduction when combined with glucocorticoids.

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

Isaacs, Bellini, and Levy discuss a currently recruiting trial investigating CGM metrics in pregnant individuals with type 1 diabetes.

Steger discussed the importance of tailoring diet strategies to patients with type 2 diabetes.

Shah discusses the stagnation of the T1D treatment landscape and the potential progress that GLP-1 RA research could present.

Philis-Tsimikas emphasized the impact of nonmedical factors on health and how clinicians can be cognizant of them in their patient management.

Shah discusses the results from the ADJUST-T1D trial comparing semaglutide to placebo, which saw a significant disparity in semaglutide’s favor.

Isaacs and Bellini discuss 3 more of the most impactful trials presented at the 85th annual American Diabetes Association conference in part 2 of this 2-part recap.

Isaacs and Bellini cover 3 of the most pivotal trial results from the 85th annual American Diabetes Association conference in part 1 of this 2-part recap.

Already approved by the FDA based on data from the first half of the PaTHway trial, 3-year extended results have indicated lasting efficacy.

Auchus discusses his recent presentation on the CATALYST trial, investigating the characteristics of patients with difficult-to-treat T2D because of hypercortisolism.

Lifestyle intervention yielded greater maintained weight loss 12 months after discontinuing semaglutide than without.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

Stay updated with the latest healthcare breakthroughs, including FDA news, clinical trial data, and regulatory submissions, in this week's essential news roundup.

Sandforth discussed his research that found that early prediabetes remission conferred greater protective effects against T2D than later remission.

Positive topline results showed patients who received 2 scheduled rilparencel injections experienced significant eGFR slope decline improvement.

Hosts discuss the US launch of the Twiist from Sequel Med Tech and what it means for care providers and people with diabetes.

Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

From uncovering new benefits of semaglutide to targeting hypercortisolism in people with type 2 diabetes, here are 5 key updates from the annual meeting.